NCT06584058

HPP737 Substance Balance Study in Human

[14C] A Single-center, Nonrandomized, Open, Single-dose Substance Balance Study of HPP737 in Healthy Subjects

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Newsoara Biopharma Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of \[14C\]HPP737, to obtain the cumulative excretion rate and main excretion routes of human radioactivity; 2. To identify the main metabolites in the offspring of \[14C\]HPP737 in healthy male subjects, and to determine the main biotransformation pathway and main metabolite structure; 3. To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total plasma radioactivity in healthy male subjects after a single oral administration of \[14C\]HPP737. Participants will: 1. Take Investigational product once 2. Stay in the clinic about 7 days for checkups and tests 3. Report their symptoms

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	HPP737	\[14C\]HPP737 oral preparation, 20mg（150μCi）, once

Timeline

• Start date: 2024-08-30
• Primary completion: 2025-07-30
• Completion: 2025-08-30
• First posted: 2024-09-04
• Last updated: 2024-09-04

Locations

1 site across 1 country: China